<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>

INVESTOR RELATIONS

Trovagene to Present at the Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City

Apr 25, 2017

SAN DIEGO, April 25, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will be presenting at the Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 at 4:00 PM EDT at the Mandarin Oriental in New York City. Management will also be available to meet with investors during the conference.

The presentation will be webcast live at http://wsw.com/webcast/pioneers2/trov and can also be accessed through the Trovagene investor relations web page at www.trovagene.com.  A replay of the presentation will be available and archived for 90 days. 

About Trovagene, Inc.

Trovagene is a biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  For more information, please visit www.trovagene.com.

Trovagene Contact

Vicki Kelemen
Sr. Director, Communications
858-952-7652
vkelemen@trovagene.com

 

SOURCE Trovagene, Inc.


PDF
email print rss pdf